These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 8541105)

  • 1. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.
    Peng B; Boddy AV; Cole M; Pearson AD; Chatelut E; Rubie H; Newell DR
    Eur J Cancer; 1995 Oct; 31A(11):1804-10. PubMed ID: 8541105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics and dose optimisation of carboplatin.
    Duffull SB; Robinson BA
    Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
    Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
    Clin Pharmacol Ther; 2000 Jun; 67(6):621-30. PubMed ID: 10872644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve.
    Ghazal-Aswad S; Calvert AH; Newell DR
    Cancer Chemother Pharmacol; 1996; 37(5):429-34. PubMed ID: 8599865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K; Gervais A; Aikin A; Egorin M; Balis FM
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial.
    Thomas H; Boddy AV; English MW; Hobson R; Imeson J; Lewis I; Morland B; Pearson AD; Pinkerton R; Price L; Stevens M; Newell DR
    J Clin Oncol; 2000 Nov; 18(21):3614-21. PubMed ID: 11054434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer.
    Johansen MJ; Madden T; Mehra RC; Wood JG; Rondon G; Browne V; Newman RA; Champlin RE
    J Clin Oncol; 1997 Apr; 15(4):1481-91. PubMed ID: 9193344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage.
    Chatelut E; Pivot X; Otto J; Chevreau C; Thyss A; Renée N; Milano G; Canal P
    Eur J Cancer; 2000 Jan; 36(2):264-9. PubMed ID: 10741287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A sequential Bayesian algorithm for dose individualisation of carboplatin.
    Duffull SB; Begg EJ; Robinson BA; Deely JJ
    Cancer Chemother Pharmacol; 1997; 39(4):317-26. PubMed ID: 9025772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.
    Newell DR; Pearson AD; Balmanno K; Price L; Wyllie RA; Keir M; Calvert AH; Lewis IJ; Pinkerton CR; Stevens MC
    J Clin Oncol; 1993 Dec; 11(12):2314-23. PubMed ID: 8246021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.
    Etienne MC; Leger F; Pivot X; Chatelut E; Bensadoun RJ; Guardiola E; Renée N; Magné N; Canal P; Milano G
    Ann Oncol; 2003 Apr; 14(4):643-7. PubMed ID: 12649114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute.
    Millward MJ; Webster LK; Toner GC; Bishop JF; Rischin D; Stokes KH; Johnston VK; Hicks R
    Aust N Z J Med; 1996 Jun; 26(3):372-9. PubMed ID: 8811211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
    Duong JK; Veal GJ; Nath CE; Shaw PJ; Errington J; Ladenstein R; Boddy AV
    Br J Clin Pharmacol; 2019 Jan; 85(1):136-146. PubMed ID: 30261554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children.
    Patoux A; Bleyzac N; Boddy AV; Doz F; Rubie H; Bastian G; Maire P; Canal P; Chatelut E
    Eur J Clin Pharmacol; 2001 Jul; 57(4):297-303. PubMed ID: 11549207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
    Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
    Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I evaluation of carboplatin by use of a dosing strategy based on a targeted area under the platinum concentration-versus-time curve and individual glomerular filtration rate in cats with tumors.
    Bailey DB; Rassnick KM; Dykes NL; Pendyala L
    Am J Vet Res; 2009 Jun; 70(6):770-6. PubMed ID: 19496668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A limited-sampling method for evaluation of the area under the curve of ultrafilterable carboplatin in children.
    Doz F; Urien S; Chatelut E; Michon J; Rubie H; Zucker JM; Canal P; Bastian G
    Cancer Chemother Pharmacol; 1998; 42(3):250-4. PubMed ID: 9685062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flat dosing of carboplatin is justified in adult patients with normal renal function.
    Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
    Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
    Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
    Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.
    Zhao W; Cella M; Della Pasqua O; Burger D; Jacqz-Aigrain E;
    Br J Clin Pharmacol; 2012 Apr; 73(4):641-50. PubMed ID: 21988586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.